Sign up
Pharma Capital

ResApp Health's shares are being snapped up

ResApp Health is a digital health company with a focus on smartphone solutions.
1506041987_looking-at-smartphone.jpg
ResApp shares have gained 4.4% to $0.071 today

ResApp Health Ltd (ASX:RAP) has received a notice of initial substantial shareholder from Ian Francis Reynolds, who now holds circa 37 million shares for a 5.6% stake.

ResApp shares are currently trading around the $0.07 range, down from above $0.30 two months ago, when it revealed some study results.

The company is working on developing a clinically-tested, regulatory-cleared respiratory disease diagnostic test and management tools for smartphones.

ResApp has a market cap in the $45 million range, and held $8.6 million in cash at the end of June 2017.

View full RAP profile

ResApp Health Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.